Published in Biotech Business Week, November 7th, 2005
Ray Akers, CEO of Akers Biosciences, said, "The second quarter of 2005 saw a distinct uplift in sales, due largely to our flagship PIFA Heparin/PH4 rapid test product. As of today, our test for heparin/PF-4 antibodies is being used in approximately 140 hospitals in the United States, and that number continues to grow by 5-10 hospitals each week.
"We gained further momentum through the receipt of other product approvals and the establishment of important distribution and business relationships, and have begun to translate this momentum into product sales. This is...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.